Report: PET utilization nudges up
An estimated 1,744,000 clinical PET patient studies were performed in the U.S. in 2010, according to the report released by IMV Medical Information Division. These PET studies were performed in 2,085 hospital and non-hospital sites, using fixed or mobile PET/CT or PET scanners.
“The estimated 1,744,000 clinical PET patient studies performed in 2010 represent a 14.7 percent increase over IMV’s estimate of 1,520,800 patient studies performed in 2008, for an average annual growth rate of 7.1 percent over the two years,” observed Lorna Young, senior director of market research at IMV. “This represents a slowing in the annual growth rate for PET patient studies, as the average annual rate between 2005 and 2008 was 10.4 percent. However, the annual 7 percent rate for procedures is still a significant growth rate, in an era of increased scrutiny of third party insurers in their pre-authorization processes.”
Currently, PET technology is utilized primarily for oncology applications, which comprise 95 percent of PET studies. Neurology and cardiology applications make up the remaining 5 percent, and are likely to become a larger proportion of PET studies, as other radiopharmaceutical tracers, such as PET agents for Alzheimer’s disease, become approved for clinical use.
“In parallel with the continued evolution of the clinical utility of PET, the number of sites using fixed PET technology is increasing access to PET imaging. Although the number of sites performing PET imaging using fixed or mobile PET increased only 4 percent from 2,000 sites in 2008 to the current 2,085 sites, the mix of sites using fixed units versus mobile PET services has dramatically shifted.”
Over half of sites, 1,150 sites, now use fixed PET imaging units, compared with one-third of the sites providing PET imaging in 2003, the report found. With this increased access, the median waiting time for a scheduled outpatient appointment at sites using fixed or mobile PET or PET/CT scanners is four days, down from seven days in 2001.
“Also, we see a sizable shift of sites using fixed PET/CTs compared to fixed PET scanners,” wrote the report authors. “When PET/CT came into the market around 2003, it was adopted rapidly, due to its unparalleled capability to image both anatomical structures and metabolic activity. In 2003, one-third of the installed base was PET/CT scanners, but now, about 90 percent of the fixed units are PET/CTs.”
The market for PET scanners was affected by the general economic downturn in 2008, which, coupled with the near completion of the replacement of the PET only scanners with PET/CTs, may result in a slow recovery for unit sales, the report noted. However, approximately 45 percent of the PET imaging sites currently use mobile services, and they may purchase their first fixed unit as they grow their volume and referrals.
“Newly introduced technology such as PET/MR may stimulate the demand for additional units in the larger PET centers,” the authors predicted. “Over the next few years, about half of the PET scanner demand will come from first buyers, who are primarily mobile users, about one third will be replacement buyers and the remaining purchases will be for additional units.”
Other report highlights included:
- The top PET oncology applications are respiratory, breast cancer, lymphoma and colorectal cancer.
- Ninety-four percent of PET patient studies used radiopharmaceuticals purchased from an outside supplier and 6 percent were obtained from cyclotrons onsite.
- The five states with the highest PET patient study volume are Florida, California, New York, Texas and Pennsylvania.
The report described trends in PET and PET/CT patient studies by procedure type, PET and PET/CT installed base by manufacturer and year of installation, planned purchases and market scenarios for unit sales through 2015, radiopharmaceutical utilization and expenditures by supplier, and site operations characteristics.